Press Releases
  Date Title View
Rockville, MD, January 27, 2010 – Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus basel...
Posted: Jan 27, 2010
Rockville, MD, July 28, 2009 — Supernus Pharmaceuticals, Inc. today announced that it recently closed a second non-dilutive financing transaction that brings the total funds raised to date against royalties from its partnered products to more than $110 million. In April 2008, the company announced a $75 million t...
Posted: Jul 28, 2009
Rockville, MD., January 30, 2009 — Supernus Pharmaceuticals Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN810 in the treatment of serious conduct problems in the setting of ADHD. The trial is a proof-of-concept, open-label study with pediatric subjects randomiz...
Posted: Jan 30, 2009
Rockville, MD., December 17, 2008 — Supernus Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase III clinical trial for its lead product SPN-804. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of SPN-804 for the adjunctive treatment o...
Posted: Dec 17, 2008
Rockville, MD, April 23, 2008 — Supernus Pharmaceuticals, Inc. today announced that it closed a private placement to institutional investors of $75 million in aggregate principal amount of non-convertible, non-recourse promissory notes. The notes are secured by royalties generated from sales of Oracea®...
Posted: Apr 23, 2008
September 19, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Allergan, Inc. (NYSE: AGN), through its acquisition of Esprit Pharma, has obtained the United States rights to Sanctura® and Sanctura® XR. CONTACT: Russell "Rip" Wilson Chief Financial Officer Supe...
Posted: Sep 19, 2007
August 6, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Sanctura® XR (trospium chloride extended release capsules) has been approved by the U.S. Food and Drug Administration (FDA). CONTACT: Russell "Rip" Wilson Chief Financial Officer Supernus Pharmaceu...
Posted: Aug 6, 2007
Posted: Jun 26, 2006
Posted: Jun 13, 2006
Rockville, MD, February 21, 2006 - Supernus Pharmaceuticals, Inc., announces the closing of a second round of financing raising an additional $17.5 million. This completes the Series A funding for a total of $45 million. The company announced last month the closing of the first round of financing and the acquisition of substantially all the as...
Posted: Feb 21, 2006
FirstPrevious
...
16
NextLast
= add release to Briefcase